GlassScriptPhysician profile
Karim M Fram
NPI 1265478671
$6,486.78
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,684 · 2020: $897 · 2021: $2,716 · 2022: $1,190.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $870.18 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $661.38 | 2019-2022 | |
| Ucb, INC. | $530.44 | 2019-2022 | |
| Mdd US Operations, LLC | $378.16 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $373.84 | 2019-2021 | |
| Emd Serono, INC. | $313.60 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $275.22 | 2019-2022 | |
| Abbvie INC. | $252.23 | 2019-2021 | |
| Sk Life Science, INC. | $250.66 | 2020-2022 | |
| Amgen INC. | $221.72 | 2019-2022 | |
| Eisai INC. | $176.18 | 2019-2022 | |
| Genentech USA, INC. | $172.83 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $150.62 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $140.08 | 2019-2021 | |
| Horizon Therapeutics Plc | $109.06 | 2021-2022 |
Show all 44 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karim Fram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.